Table 1.
Baseline characteristics of study participants.
| Variables | n = 39 | Men (n=15) | Women (n=24) | p4 | |||
|---|---|---|---|---|---|---|---|
| Age (mean (SD)) | 46.51 (11.11) years | 46.7 (9.1) years | 46.4 (12.4) years | 0.923 | |||
| Phenotype | Relapsing-Remitting | 27 (69.2%) | 9 (60%) | 15 (75%) | 0.014 | ||
| Secondary Progressive | 4 (10.3%) | 0 | 4 (17%) | ||||
| Primary Progressive | 8 (20.5%) | 6 (40%) | 2 (8%) | ||||
| EDSS* score (median (range)) | 3 (1 – 7) | 3.9 (1.7) | 3.4 (1.7) | 0.328 | |||
| SDMT* score (median (range)) | 52 (29 – 83) | 47.4 (7.3) | 54.7 (14.0) | 0.040 | |||
| MFIS* score (median (range)) | 41 (0 – 84) | 38.2 (15.9) | 43.0 (24.8) | 0.511 | |||
| PASAT*1 (median (range)) | 43 (1 – 60) | 47.2 (9.3) | 41.0 (14.3) | 0.144 | |||
| 9HPT2 | 38 (16 – 403) | 60.7 (97.1) | 24.3 (10.2) | 0.170 | |||
| T25FW3 | 7 (4 – 28) | 5.7 (1.8) | 7.3 (5.9) | 0.228 | |||
| On Disease-Modifying Therapy | 27 (69.2%) | 12 (80%) | 15 (63%) | 0.426 | |||
| Interferon Beta-1a | 4 | 2 (13%) | 2 (8%) | ||||
| Glatiramer acetate | 5 | 2 (13%) | 3 (13%) | ||||
| Natalizumab | 3 | 1 (7% | 2 (8%) | ||||
| Teriflunomide | 1 | 0 | 1 (4%) | ||||
| Fingolimod | 4 | 2 (13%) | 2 (8%) | ||||
| Dimethyl fumarate | 10 | 5 (33%) | 5 (21%) | ||||
| Duration of Symptoms (mean (SD)) | 12.33 (8.60) years | 8.9 (5.8) years | 14.5 (9.5) years | 0.028 | |||
| Follow-up (mean (SD)) | 1.48 (0.98) years | 1.42 (0.95) years | 1.58 (1.05) years | 0.628 | |||
9HPT = 9-Hole Peg Test; T25FW = Timed 25-Foot Walk; EDSS = Expanded Disability Status Scale; PASAT = Paced Auditory Serial Addition Test; SD = standard deviation; SDMT = Symbol Digit Modalities Test; MFIS = Modified Fatigue Impact Scale.
*
at baseline visit
1
2 values missing
2
average of dominant and non-dominant hands
3
average of two trials
4
difference between men and women. Chi-square test was used for categorical variables (phenotype, use of disease-modifying therapy); independent samples t-test was used for the remaining continuous variables